Reducing the number of molecular diagnostics vendors can meaningfully cut costs and simplify clinical workflows, but only if clinicians fully trust the results. This session covers how oncology leaders evaluate vendor consolidation, carefully manage the transition, and maintain physician confidence in test accuracy and turnaround throughout the entire process.